1. Angiotensin Inhibitor Use is Associated with Longer Survival in Resected Pancreatic Cancer. (2022) Authors: Liu, H.; Nassour, I.; Lebowitz, S.; D'Alesio, M.; Hampton, E.; Desilva, A.; Samer, A.M.; Hammad, A.; Singhi, A.; Bahary, N.; Lee, K.; Zureikat, A.; Paniccia, A. Journal: HPB Issue: Volume 24(2022)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Angiotensin system inhibitor use is associated with longer survival in resected pancreatic cancer. (2021) Authors: Liu, H.; D'Alesio, M.; Lebowitz, S.; Hammad, A.; Nassour, I.; Singhi, A.; Bahary, N.; Lee, K.; Zureikat, A.; Paniccia, A. Journal: HPB Issue: Volume 23(2021)Supplement 2 Page Start: S466 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CA19-9 reduction correlates to histopathologic tumor response following neoadjuvant chemotherapy in pancreatic adenocarcinoma. (2021) Authors: Kim, V.M.; AlMasri, S.; Zenati, M.; Hoehn, R.S.; Hammad, A.Y.; Singhi, A.D.; Bahary, N.; Ellsworth, S.G.; Lee, K.K.; Paniccia, A.; Zureikat, A.H. Journal: HPB Issue: Volume 23(2021)Supplement 2 Page Start: S504 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Is Adjuvant Chemotherapy Needed in Surgically Resected Pancreatic Carcinoma with Node Negative Disease Following Neoadjuvant Therapy? A Multi-Institutional Analysis. (2022) Authors: Hammad, A.; Almasri, S.; Hodges, J.; Paniccia, A.; Lee, K.; Bahary, N.; Singhi, A.; Ellsworth, S.; Evans, D.; Tsai, S.; Zureikat, A. Journal: HPB Issue: Volume 24(2022)Supplement 1 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Neoadjuvant Chemotherapy Resulting in Suboptimal CA19-9 Response is Associated with No Survival Benefit Compared to Surgery First Approach in Resectable or Borderline Resectable Pancreatic Cancer. (2022) Authors: Liu, H.; D'Alesio, M.; Al Masri, S.; Hammad, A.; Desilva, A.; Ashwat, E.; Hampton, E.; Lebowitz, S.; Singhi, A.; Bahary, N.; Lee, K.; Zureikat, A.; Paniccia, A. Journal: HPB Issue: Volume 24(2022)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Neoadjuvant folfirinox in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis. (2020) Authors: Buettner, S.; Janssen, Q.; Suker, M.; Beumer, B.; Addeo, P.; Bachellier, P.; Bahary, N.; Bekaii-Saab, T.; Bali, M.; Besselink, M.; Boone, B.; Chau, I.; Clarke, S.; Dillhoff, M.; El-Rayes, B.; Frakes, J.; Grose, D.; Hosein, P.; Jamieson, N.; Javed, A. Journal: HPB Issue: Volume 22(2020)Supplement 2 Page Start: S327 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Presence of perineural invasion determines the need for adjuvant chemotherapy in resected pancreatic carcinoma with node negative disease following neoadjuvant therapy; a multi-institutional analysis. (2021) Authors: Hammad, A.Y.; AlMasri, S.; Hodges, J.C.; Paniccia, A.; Lee, K.K.; Bahary, N.; Singhi, A.; Aldakkak, M.; Evans, D.B.; Tsai, S.; Zureikat, A. Journal: HPB Issue: Volume 23(2021)Supplement 2 Page Start: S487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The systemic immune-inflammation index (SII) predicts neoadjuvant therapy response and survival in patients with pancreatic cancer who are CA 19-9 non-secretors. (2021) Authors: Murthy, P.; Zenati, M.; AlMasri, S.; DeSilva, A.; Bahary, N.; Singhi, A.; Ellsworth, S.; Paniccia, A.; Lee, K.; Lotze, M.; Zureikat, A. Journal: HPB Issue: Volume 23(2021)Supplement 2 Page Start: S457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗